Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
279 6 |
Ultima descărcare din IBN: 2024-03-28 15:19 |
Căutarea după subiecte similare conform CZU |
618.31-006.882-07-036 (1) |
Științe medicale. Medicină (11143) |
SM ISO690:2012 GRECICHINA, Ecaterina, FULGA, Veaceslav, SINIŢÎNA, Lilia, GLOBA, Tatiana, DAVID, Valeriu. Evaluation of BCL2 expression in early hydatiform mole. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 24. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | |||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | |||||||
|
|||||||
CZU: 618.31-006.882-07-036 | |||||||
Pag. 24-24 | |||||||
|
|||||||
Descarcă PDF | |||||||
Rezumat | |||||||
Background. The gestational trophoblastic disease is a heterogeneous group of trophoblast proliferative lesions involving cyto-syncitiotrophoblast. The establishing of a marker by immunohistochemical investigations could influence the diagnostic of molar pathology. Objective of the study. Evaluation of anti-BCL2 immunoexpression in the epithelial compartment of the villous trophoblast in the hydatidiform mole. Material and Methods. Abortion product from 15 patients diagnosed with hydatidiform mole by ultrasound and morphological imaging with anti-p57 (NCL-L-p57, clone 25B2, dilution: 1: 100, incubation period 30 min) and marker for Bcl2 protein: anti-Bcl2 (oncoprotein, clone 124, incubation period 25 min). Detection system: NovolinkTM MaxPolymer (RE7280-K, Leica). Results. The hydatidiform mole was distributed according to the differentiated antip57 immunoexpression in the villous trophoblast into: MHC - 8 cases (53.35%) vs MHP - 7 cases (46.6%). Immunoexpression in the villous trophoblast was as follows: the positive reaction was attested in 100% of cases in the syncytiotrophoblastic component, and in the cytotrophoblast it was negative. The endometrial (immunopositive) glands served as a positive internal control. Negative control - replacement of the primary antibody TRIS-buffer saline. Conclusion. Differentiated immunoexpression of BCL2 protein in the trophoblastic compartment of chorionic villi allows the evaluation of the trophoblastic epithelial profile in gestational molar pathology. |
|||||||
Cuvinte-cheie anti-BCL2, hydatidiform mole, molar pregnancy, trophoblastic disease, anti-BCL2, mola hidatiformă, sarcină molară, boală trofoblastică |
|||||||
|